Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT06236438 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06236438
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06236438 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
AbbVie
Phase
Phase 2/3
Overall status
Recruiting
Start date
April 10, 2024
Completion date
October 31, 2031
Enrollment
840 (estimated)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer